Biopharma News

Big pharma companies Novartis, Amgen, and Bristol-Myers Squibb announce positive third-quarter 2013 results.

Amarin cuts staff in half after an FDA committee rejects its product label expansion.

Abbott?s third-quarter 2013 global sales increased slightly but were affected by a disruption in the International Nutrition business.

J&J announces 2013 third-quarter sales increased 3% over 2012 third-quarter sales.

MedImmune expands its antibody-drug conjugate capability through acquisition and collaboration.

GlaxoSmithKline?s sale of its thrombosis brands is part of a focus on its late-stage pipeline.

Merck announced plans to reduce its workforce by 8,500 and move its headquarters in order to sharpen its commercial and R&D focus.

Merck & Co. has received a Complete Response Letter from FDA for the resubmission of its new drug application for sugammadex sodium injection.

J&J's Janssen and PATH partner to improve drug formulation that could help prevent HIV infection.

AstraZeneca, Bristol-Myers Squibb recall certain lots of of their antidiabetes drug Bydureon (eventide) due to manufacturing records that batches may contain underfilled vials.

Unilife grants Sanofi long-term exclusivity for the use of Unilife?s prefilled syringe with Sanofi?s Lovenox.

Myriad Genetics and AstraZeneca expand their companion diagnostic pact for AztraZeneca?s investigational drug candidate olaparib.

Following passage in the California Assembly, the California State Senate passes legislation to specify requirements for dispensing biosimilars.

Zealand will join efforts with Eli Lilly to design and develop therapeutic peptides for Type 2 diabetes and obesity.

Amarin released the submission of an sNDA to FDA seeking approval for Novasep Group.

Sanofi Pasteur has purchased Freeslate?s Biologics Formulation System for accelerating research in vaccine and protein formulation development.

Santaris Pharma and Shire have extended their partnership in the rare genetic disease space.

Vical's restructuring will leave the company with approximately 74 employees.

Amgen, Servier collaborate ivabraline and other cardiovascular products.

ScinoPharm Changshu Pharmaceuticals and Sundia MediTech form an alliance for contract research and manufacturing services in mainland China.

uniQure B.V. announced it has commenced build-out of a 55,000 ft2 US manufacturing plant in Lexington, Mass.

The licensed cell line combines BioWa's engineered glycosylation Potelligent Technology with Lonza's GS Gene Expression System.

A loan from the Province of Nova Scotia will support Immunovaccine's clinical studies through 2016.

iQur announced that it has been granted 5 million EUR ($6.6 million) by the European Union Framework 7 fund to develop a universal influenza vaccine.

Immunocore Limited has entered into a partnership with GlaxoSmithKline for multiple novel targets not addressable using antibody-based technologies.

The $1-billion deal includes select parts of Merck?s manufacturing site in Oss, The Netherlands and Sioux City, Iowa as well as 11 finished products.

The companies agree to jointly develop and promote MOR202, an oncology mAb in a deal potentially valued at more than $800 million.

FDA Discovers Microbial Contamination in Compound Pharmacy Products